Buy Mazdutide Peptide for Sale in Australia

If you want to buy Mazdutide online in Australia, you must first understand its regulatory status. Mazdutide is a once-weekly dual GLP-1 and glucagon receptor agonist developed for weight management and type 2 diabetes. It has received approval in China, yet it remains unapproved by the TGA in Australia. Therefore, you cannot legally buy Mazdutide online in Australia for human use through ordinary retail or research-chemical channels. Access requires formal medical pathways such as the Special Access Scheme or Authorised Prescriber arrangements.

This guide explains what Mazdutide is, the published clinical data, typical dosing context from trials, safety profile, Australian regulations, and the only legitimate routes to obtain it.

What Is Mazdutide?

Mazdutide (also known as IBI362 or LY3305677) is a synthetic peptide analogue of oxyntomodulin. It activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual action aims to reduce appetite, slow gastric emptying, improve glucose control and increase energy expenditure.

Innovent Biologics developed the molecule under licence from Eli Lilly for the Greater China region. China’s National Medical Products Administration (NMPA) approved it in 2025 for chronic weight management in adults with overweight or obesity (with at least one weight-related comorbidity) and later for glycaemic control in type 2 diabetes. You can review the primary Phase 3 publication in the New England Journal of Medicine.

Importantly, the TGA has not included Mazdutide on the Australian Register of Therapeutic Goods. The FDA and EMA have also not approved it.

How Mazdutide Works

Mazdutide binds GLP-1 receptors in the brain and gut, which reduces food intake and improves insulin secretion. At the same time, glucagon receptor activation may increase energy expenditure and support fat metabolism in the liver. Consequently, clinical trials have shown both substantial weight loss and improvements in metabolic markers.

The peptide is formulated for once-weekly subcutaneous injection. For related reading on incretin therapies available in Australia, see our internal guide on GLP-1 and dual agonists in Australia.

Clinical Research Results

Phase 3 trials conducted in China provide the strongest evidence. The table below summarises key findings from major studies.

Additional data show meaningful reductions in liver fat content in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Official TGA information on unapproved products is available here.

Side Effects and Safety

The most common adverse events in trials were gastrointestinal and generally mild to moderate. These include nausea, vomiting, diarrhoea, decreased appetite and constipation. Rates were higher during dose escalation and tended to lessen over time. Discontinuation due to adverse events remained low (under 3% in most arms).

As with other GLP-1-based agents, potential risks include gallbladder events, pancreatitis (rare) and the need for careful monitoring in patients with certain gastrointestinal or thyroid histories. Long-term cardiovascular outcome data outside the Chinese trial populations are still limited.

Is It Legal to Buy Mazdutide Online in Australia?

No — not through ordinary online channels. Mazdutide is an unapproved therapeutic good in Australia. Supply, advertising or importation for human use without TGA authorisation is unlawful.

The TGA and Australian Border Force actively monitor and intercept unapproved injectable weight-loss products. “Research use only” labelling does not legalise personal human use. Full TGA guidance appears on their official unapproved peptide and product safety page.

Legitimate access is possible only via:

• Special Access Scheme (SAS)
• Authorised Prescriber pathway
• Clinical trial participation (if available)

How to Access Mazdutide Legally in Australia

Follow these steps if a clinician considers Mazdutide appropriate. First, consult a registered Australian medical specialist experienced in obesity or endocrinology. Next, the doctor assesses whether an SAS Category B or Authorised Prescriber application is justified. Then, if TGA approval is granted, a licensed pharmacy or importer supplies the product under controlled conditions. Finally, use occurs only under ongoing medical supervision with regular monitoring.

Avoid overseas websites, social-media sellers and unmarked vials. Those sources cannot guarantee identity, purity, sterility or correct dosing, and possession can attract penalties. For clinic options, see our list of weight-management specialists in Australia.

Frequently Asked Questions About Buying Mazdutide Online in Australia

Can I buy Mazdutide online in Australia without special approval? No. It is not TGA-approved and cannot be supplied for human use through ordinary retail or research-chemical pathways.

How does Mazdutide compare with semaglutide or tirzepatide? Mazdutide is a GLP-1/glucagon dual agonist, whereas semaglutide is a selective GLP-1 agonist and tirzepatide is a GIP/GLP-1 dual agonist. Head-to-head data outside China remain limited.

What purity or quality should I expect? Any product obtained outside formal medical channels carries unknown quality risks. Legitimate supply under SAS or Authorised Prescriber pathways follows pharmaceutical standards.

Is Mazdutide a peptide? Yes. It is a synthetic peptide designed for once-weekly subcutaneous injection.

Is long-term use safe? Phase 3 data up to 48–60 weeks show an acceptable safety profile dominated by gastrointestinal effects. Longer-term and broader-population data are still emerging.